Ulcerative Colitis

Inflammatory bowel disease affecting the colon and rectum continuously1. Involves the gut microbiome and a dysregulated immune response. Curcumin and multi-strain probiotics have trial evidence as add-ons to medical treatment; no diet has been shown to induce remission.

Gut & Digestive Evidence-Based

Last updated:

โš ๏ธ Medication safety: please read first. The nutrition and supplement approaches on this page are meant to work alongside your prescribed treatment, never to replace it. Never stop, reduce or change your colitis medication without your prescriber's guidance. Doing so can be dangerous. Several supplements interact with colitis medication, so talk to your prescriber or pharmacist before starting anything on this page.

What Is Ulcerative Colitis?

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that causes continuous inflammation and ulcers in the innermost lining (mucosa) of the colon and rectum. Unlike Crohn's disease, UC affects only the colon: the inflammation usually starts at the rectum and spreads up the colon without skipped segments, staying in the lining.

UC is thought to involve a complex interplay: genetic susceptibility (over 200 genes identified), changes in the gut microbiome, intestinal barrier dysfunction and dysregulated immune response. The bacterial-immune dialogue at the colonic mucosa goes awry: the immune system attacks the colon as if it were a foreign invader, while the gut microbiome composition shifts toward inflammatory species.

UC typically follows a relapsing-remitting course: periods of active inflammation (flares) alternate with remission. Stress, infections, changes in medicines and some foods can set off flares. Surgery to remove the colon stops the colitis from coming back; otherwise, prescribed medicines bring on remission and keep it, with diet and lifestyle in support.

โš ๏ธ Long-standing UC (8+ years), especially with extensive colon involvement, increases colorectal cancer risk significantly. Surveillance colonoscopy with biopsies from around 8 years after diagnosis is standard, with intervals set by risk.2 Inflammation control reduces cancer risk.
A torso with the large intestine drawn on it, red and inflamed from the rectum upward without a gap and healthy above, close-ups of a healthy colon and an inflamed colon, and icons for abdominal pain, diarrhea, weight loss and fatigue

UC Classified by Extent

Proctitis / Proctosigmoiditis

Inflammation limited to rectum (proctitis) or rectum + sigmoid (proctosigmoiditis). Most common at diagnosis. Often responsive to topical (rectal) therapies. Lower colon cancer risk than extensive disease.

Left-Sided Colitis

Inflammation extends from rectum to the splenic flexure (descending colon). Symptoms more pronounced. Requires combination of topical and systemic therapy.

Pancolitis (Extensive Colitis)

Inflammation extends past splenic flexure, often affecting entire colon. Higher risk of complications (toxic megacolon3, perforation, dysplasia, colorectal cancer). More aggressive therapy required.

Ulcerative Colitis by the Numbers

600K to 900K
people in the US have ulcerative colitis (NIDDK)4
15 to 30
years, the peak age at diagnosis, with a second peak between 50 and 80 (NIDDK and a 2019 review)23
~10%
need colectomy within 10 years in cohorts since 2000 (population-based studies)5
2 to 3ร—
the colorectal cancer risk in long-standing pancolitis, which is why surveillance colonoscopy is offered (cohort studies)2
29%
reached clinical remission on an oral aminosalicylate against 17% on placebo, across 11 trials in 2,387 adults with active colitis6
4.7%
relapsed over six months when curcumin was added to maintenance medicine, against 20.5% on placebo, in one trial of 89 people7

Symptoms of Ulcerative Colitis

Symptoms vary by severity (mild, moderate, severe, fulminant) and extent. Bloody diarrhea is the hallmark. Extraintestinal manifestations also occurred in 31% of people with UC in a Swiss cohort8.

SymptomWhat happens
Intestinal Symptoms
Bloody Diarrhea (Hallmark)Frequent loose stools with visible blood and/or mucus. Number of bowel movements correlates with severity: <4/day mild; 4 to 6 moderate; >6 with systemic symptoms severe. Often nocturnal stools wake patient.
Urgency & TenesmusTenesmus = painful, ineffective urge to defecate. Sudden, urgent need to use bathroom (sometimes can't make it). Profoundly impacts quality of life; common to confine activities near bathroom access.
Abdominal CrampingEspecially in left lower quadrant (sigmoid colon). Cramps often precede or accompany bowel movements. Relieved (transiently) by defecation.
Weight Loss & Reduced AppetiteFrom malabsorption, inflammation and reduced intake during flares. Significant weight loss indicates active disease or severe flare.
Extraintestinal Manifestations
Arthritis & Joint PainPeripheral arthritis (large joints, parallels disease activity) OR axial spondyloarthritis (spine, independent of disease activity). Arthritis was recorded in 21% of people with UC in the same Swiss cohort8.
Eye Inflammation (Uveitis, Episcleritis)Painful red eye, vision changes, light sensitivity. Requires urgent ophthalmology evaluation; uveitis can damage vision permanently.
Skin LesionsErythema nodosum (painful red shins) and pyoderma gangrenosum (ulcerating skin lesions) both reflect systemic inflammation tied to UC activity.
Primary Sclerosing Cholangitis (PSC)Liver/bile duct inflammation, found in about 4% of people with UC in a Swiss cohort. Causes elevated alkaline phosphatase, fatigue, pruritus. Raises the risk of colorectal and bile duct cancer8.

Causes of Ulcerative Colitis

Doctors are not sure what causes ulcerative colitis; genes, an abnormal immune reaction, gut microbes and environment are thought to play a part4. Several things are known to set off flares9.

CauseHow It Contributes to Ulcerative ColitisWhat Helps
Immune reaction, in people with a genetic tendencyAbnormal immune reactions inflame the large intestine, and a parent, sibling or child with IBD raises risk4.Prescribed anti-inflammatory medicines: aminosalicylates for mild to moderate colitis; short steroid courses for flares; immunosuppressants, biologics or small molecule medicines for moderate to severe colitis (conventional care)4
Gut microbesThe gut microbes of people with IBD differ from those of people without it, but their role is still being studied4.A high-strength multi-strain probiotic alongside medical treatment, which helped induce remission in mild to moderate colitis10 (Supplement Protocol)
Stopping or changing medicines (flares)Changes in medicines can set off a flare9.Taking prescribed medicines even when you feel well (conventional care)9
Anti-inflammatory painkillers (flares)Nonsteroidal anti-inflammatory painkillers can set off flares and make symptoms worse94.Not taking them unless a doctor prescribes them, and asking which pain relief suits you (conventional care)
Gut infections (flares)Infections can set off a flare9, and an infection can look like a flare.Stool tests during a flare, including for C. difficile, before treatment is changed (conventional care; Diagnosis)
Stress and some foods (flares)Stress and certain foods can set off flares, though trigger foods differ between people9.Ways to manage stress, such as breathing exercises, and a food diary, with diet changes agreed on with your care team (conventional care)9

How Ulcerative Colitis Is Diagnosed

TestWhat it shows
Diagnosis
Colonoscopy with Biopsy (Gold Standard)Direct visualization of continuous mucosal inflammation starting at the rectum. Biopsies show characteristic chronic inflammation, crypt abscesses, distorted crypt architecture. Distinguishes UC from Crohn's and other colitis types.
Fecal CalprotectinNon-invasive marker of gut inflammation. Helps distinguish IBD from IBS; monitors flare vs remission. <50 ยตg/g normal; >250 suggests active inflammation.
CBC, CRP, ESR, Iron StudiesAnemia (chronic blood loss), elevated CRP/ESR (systemic inflammation), low albumin (severe disease). Help assess severity and chronicity.
Monitoring & Cancer Surveillance
Routine Disease Activity MonitoringQuarterly to annual fecal calprotectin during active disease/​medication changes. CRP and CBC. Clinical assessment via Mayo or Truelove-Witts scoring systems.
Surveillance ColonoscopyStarting 8 years after diagnosis (or earlier if PSC), every 1 to 3 years depending on risk factors. Multiple random biopsies to detect dysplasia. Cancer prevention is critical.
Stool Studies for InfectionDuring flares, rule out C. difficile (common in IBD), CMV, parasites. Infection mimics flares and changes treatment significantly.
Nutritional & Liver WorkupVitamin D, B12, iron, folate, zinc, magnesium often deficient. Liver enzymes annually to screen for PSC. DXA scan if on chronic steroids.

Conventional and Holistic Treatment for Ulcerative Colitis

๐ŸŒฟ HOLISTIC
๐Ÿ’Š CONVENTIONAL
๐ŸŒฟ

Holistic / Functional Approach

Anti-inflammatory diet (SCD, IBD-AID, Mediterranean) + curcumin + stress management

Specific Carbohydrate Diet11
Some supportive data, mostly small studies; no diet has been shown to induce remission in UC
Curcumin
In one randomized trial, relapse at six months fell from 20.5% to 4.7% when added to mesalamine maintenance7
Timeline
Any benefit from diet or supplements is gradual and is judged alongside conventional treatment, not in place of it
Advantage
May add to medical treatment; curcumin and multi-strain probiotics have trial evidence as add-ons

Full Holistic Approach Includes

  • Specific Carbohydrate Diet (SCD) or IBD-AID, some supportive data, but no diet has been shown to induce remission in UC.
  • Mediterranean diet for maintenance, anti-inflammatory polyphenols, fatty fish, fiber from tolerated sources
  • Curcumin (turmeric extract) 1 to 3 g/day, one randomized trial found fewer relapses when added to mesalamine. Liver injury has been reported with high-dose, high-absorption curcumin products; stop and seek advice if you notice dark urine or yellowing skin.
  • Omega-⁠3 EPA/DHA, not recommended: pooled trials found no evidence that it keeps UC in remission12
  • Vitamin D3: deficiency is common in UC; correct it with your clinician. Test 25-⁠OH-D first and set the dose with your clinician. Dosing limits: the adult tolerable upper intake level is 4,000 IU/day. The Endocrine Society's 2024 guideline found no clear evidence for an optimal target level; the National Academies (formerly the Institute of Medicine) set sufficiency at 20 ng/mL (50 nmol/L). Any dose above 4,000 IU/day needs a blood test and a clinician, not a self-directed dose.
  • Targeted probiotics: high-strength multi-strain probiotics10 have the strongest UC evidence; they helped induce remission in mild to moderate UC and reduced recurrence in relapsing pouchitis. Saccharomyces boulardii's evidence is for antibiotic-associated diarrhea rather than UC.
  • Boswellia serrata 350 mg 3x/day, anti-inflammatory; one small 6-⁠week trial found remission rates similar to a standard anti-inflammatory medicine13
  • L-Glutamine + butyrate, fuel for the cells lining the colon; small trials of butyrate enemas in distal UC have had mixed results, so ask your gastroenterologist first.
  • Address food triggers, such as alcohol, carbonated drinks and raw cruciferous vegetables during flares; get tested for celiac disease before cutting out gluten; if dairy seems to worsen symptoms, test a short elimination and reintroduction with your care team, since cutting out dairy may harm bone health
  • Stress management: stress can set off flares, and breathing exercises are one way to manage it9
โš ๏ธ Critical: Holistic approaches work alongside, never instead of, prescribed treatment at every severity of UC. Discuss any supplement changes with your gastroenterologist; some interact with immunosuppressants.

Evidence-Based Supplements for Ulcerative Colitis

Some of these supplements have randomized trial evidence in UC; others rest on smaller studies. Use as adjuncts to medical therapy, with gastroenterologist awareness.

SupplementWhat it is forTypical rangeTimingNotes & cautions
Curcumin (Turmeric Extract)NF-ฮบB inhibition, broad anti-inflammatory. A randomized trial of curcumin added to mesalamine maintenance (a 2006 trial of 89 patients) found relapse at six months of 4.7% against 20.5% on placebo. This is one modest-sized trial; a separate trial of curcumin for inducing remission was also positive.71 to 3 g/dayWith meals, dividedAvoid with anticoagulants. Liver injury has been reported with high-dose, high-absorption curcumin products; stop and seek advice if you notice dark urine or yellowing skin17.
Boswellia serrataInhibits 5-⁠lipoxygenase, reducing leukotriene-mediated inflammation. One small 6-⁠week trial found remission in 82% against 75% on an aminosalicylate; the evidence rests on small, short trials13.350 mg 3x/dayWith mealsStandardized to โ‰ฅ65% boswellic acids. AKBA-enriched products may be more potent.
Omega-⁠3 EPA/DHAAnti-inflammatory eicosanoid production. A Cochrane review of three trials in 138 people found no evidence that it keeps UC in remission12.Not recommended for keeping UC in remission (reviews of the trials found no benefit)Not applicableEat fatty fish such as wild salmon or sardines instead. In heart trials, fish oil supplements raised the risk of atrial fibrillation, an irregular heartbeat, more so above 1 g a day18, so check any fish oil supplement with your clinician first.
Vitamin D3Low vitamin D is common in UC. Correct a deficiency with your clinician; there is no agreed optimal target level.Test 25-⁠OH-D first and set the dose with your clinicianWith fat mealTest 25-⁠OH-D every 3 to 6 months.
High-Strength Multi-Strain ProbioticStrongest probiotic evidence in UC. An overview of systematic reviews found it helped induce remission in mild to moderate UC and reduced recurrence in relapsing pouchitis10.900 billion CFU a day during active disease; 450 billion a day for maintenanceWith mealsRefrigerated formulations preferred for viability. Use caution with a weakened immune system or a central line, as bloodstream infections from probiotics have been reported; agree on it with your team.
S. boulardiiSome evidence for antibiotic-associated diarrhea. It is not a treatment for C. difficile, which needs prescribed antibiotics.500 mg (about 10 billion CFU) twice a day, for antibiotic-associated diarrheaWith mealsNot shown to help UC. Use caution with a weakened immune system or a central line, as bloodstream infections from probiotics have been reported; agree on it with your team.
Iron (IV preferred in active UC)Inflammation blocks iron absorption, so UK guidance advises against iron tablets during active disease19. IV iron (iron sucrose, ferric carboxymaltose) repletes deficiency without GI side effects.Per gastroenterologistNot applicableIV iron 1 to 3 doses typically repletes deficit. Avoid oral iron during flares.
L-Glutamine + ButyratePrimary fuel for the cells lining the colon (especially butyrate). Small trials of butyrate enemas in distal UC have had mixed results.Glutamine 5 to 10 g/day oral; butyrate 4 g/enemaBetween meals; enemas at bedtimeButyrate enemas require compounding pharmacy. Distinct from oral butyrate supplements.

What to Expect Over Time

Ulcerative colitis is lifelong and comes and goes; prescribed medicines bring on remission and keep it, and diet supports them rather than replacing them.

Treatment and supportive care, together
First Weeks

Colonoscopy with biopsy, blood tests and stool tests, including for infection, confirm the diagnosis9. Mild to moderate colitis usually starts with an aminosalicylate, by mouth or rectally; steroids are for flares only, and severe colitis is treated in the hospital4.

Months 1 to 3

Across 11 trials, 29% reached remission on an oral aminosalicylate against 17% on placebo6. Steroids are not used to keep remission4. Any food changes are worked out with the care team, helped by a food diary9.

Months 3 to 12

Maintenance medicine continues even when you feel well9. If colitis stays active, immunosuppressants, biologics or a small molecule medicine follow4. Curcumin added to maintenance medicine lowered relapse over six months in one trial7.

Long Term

Remission can last weeks or years, and flares from days to months49. About 1 in 10 need colectomy within 10 years5, which stops the colitis coming back9. Colonoscopy every 1 to 3 years starts 8 years after colitis began4.

When to Seek Care

Call 911 or go to the emergency department, without waiting or trying diet first, for severe abdominal pain, nonstop bleeding or large clots, vomiting blood9, a swelling abdomen, being unable to pass gas or stool22, or more than six bloody stools a day with a fever or a fast heartbeat20. Short of that, get a same-day appointment for very bad or bloody diarrhea, a fever or a fast heartbeat9.

📬

Get new guides in your inbox. Once a month: new condition guides and research updates, including the trials that did not work. Free, no spam, and you can unsubscribe in one click.

Sign up

Remission Is the Aim of Treatment

UC is a lifelong condition. Prescribed medicines bring on and keep remission for many people, and diet and lifestyle support them.

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed October 20, 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.21 Use these approaches alongside conventional therapy, not instead of it. Two things matter most. First, sustained inflammation in ulcerative colitis is not just uncomfortable; it drives colorectal cancer risk, which is why surveillance colonoscopy from around eight years after diagnosis is standard and why achieving genuine remission matters more than feeling better. Do not skip those colonoscopies. Second, an acute severe flare is a medical emergency: more than six bloody stools a day with fever, a racing pulse, anemia or a distended tender abdomen can progress to toxic megacolon, and needs hospital assessment rather than a dietary adjustment. Antimotility drugs are avoided in a severe flare for the same reason.

  1. On the disease: ulcerative colitis causes continuous mucosal inflammation beginning at the rectum and extending proximally, which distinguishes it from the patchy transmural involvement of Crohn's disease. Extent, from proctitis to pancolitis, drives both treatment choice and surveillance intervals. ↩
  2. On colorectal cancer surveillance. Long-standing extensive colitis raises colorectal cancer risk, and surveillance colonoscopy with biopsies is recommended beginning around eight years after diagnosis, with intervals set by extent, inflammation and other risk factors such as primary sclerosing cholangitis. Better inflammatory control lowers that risk, which links the two halves of this page. ↩
  3. On acute severe colitis: this is defined by frequency of bloody stools with systemic features, assessed in the hospital, and it carries a risk of toxic megacolon and perforation, both of which are indications for surgery, and delay costs lives, PubMed 39753508. Antimotility agents and opioids are avoided. Improvement in stool frequency alongside a worsening abdomen is a warning sign, not a recovery sign. ↩
  4. On causes and care: the US National Institute of Diabetes and Digestive and Kidney Diseases estimates that about 600,000 to 900,000 people in the US have ulcerative colitis, and describes genes, abnormal immune reactions, the microbiome and environment as possible causes, a higher risk with a parent, sibling or child with IBD, aminosalicylates for mild to moderate disease, steroids for flares but not maintenance, hospital care for severe disease, remission lasting weeks or years, colonoscopy every 1 to 3 years from 8 years after onset, and fulminant colitis with more than 10 bloody stools a day, fever and a fast heart rate as an emergency, NIDDK. ↩
  5. On colectomy risk: a meta-analysis of population-based cohorts found cumulative colectomy risks in ulcerative colitis of 4.0%, 8.8% and 13.3% at 1, 5 and 10 years, falling over time, with contemporary risks after 2000 of 2.8%, 7.0% and 9.6%, PubMed 33127595. ↩
  6. On oral 5-⁠ASA for inducing remission: a 2020 Cochrane review pooling 11 placebo-controlled trials in 2,387 adults with active ulcerative colitis found that 71% of people on 5-⁠ASA failed to enter clinical remission, against 83% on placebo, PubMed 32786164. The review rated this high-certainty evidence and found once-daily dosing worked as well as divided dosing. ↩
  7. On curcumin. A 2006 trial randomized 89 patients in remission to curcumin or placebo added to mesalamine maintenance and found relapse at six months of 4.65% against 20.51% (Clin Gastroenterol Hepatol. 2006;4(12):1502-⁠1506. PubMed 17101300). A separate randomized trial in 2015 found curcumin added to mesalamine improved rates of clinical and endoscopic remission in active mild to moderate disease. These are modest-sized trials with encouraging results. Bioavailability varies enormously between preparations. ↩ ↩
  8. On problems outside the gut: in a Swiss cohort of 950 adults with inflammatory bowel disease, 31% of the 370 with ulcerative colitis had at least one, including arthritis (21%), primary sclerosing cholangitis (4%) and uveitis (4%), PubMed 20808297. In a later analysis of the same cohort, about 4% of 1,188 people with ulcerative colitis had primary sclerosing cholangitis; they developed colorectal cancer more often than those without it, and 7% of people with it developed bile duct cancer over a median of about six years, PubMed 27622999. ↩
  9. On flares and when to get help: the NHS lists stress, infections, changes in medicines, anti-inflammatory painkillers and certain foods as flare triggers, notes flares last from a few days to several months, advises taking prescribed medicines even when well, and advises emergency care for severe abdominal pain, nonstop bleeding or vomiting blood, and an urgent same-day appointment for very bad or bloody diarrhea, fever or a fast heartbeat, NHS. ↩
  10. On probiotics: high-strength multi-strain preparations have the best randomized evidence of any probiotic in this area, in pouchitis after ileal pouch-anal anastomosis and, less strongly, in ulcerative colitis. An overview of systematic reviews found probiotics reduced recurrence in relapsing pouchitis and helped induce remission in mild to moderate ulcerative colitis, found no protective effect in Crohn's disease, and found multi-strain formulations superior to single strains, PubMed 39106167. So this evidence does not transfer to Crohn's, and effects are formulation-specific: results for one product do not carry over to another. ↩
  11. On diet: no diet has been shown to induce remission in ulcerative colitis in the way exclusive enteral nutrition does in pediatric Crohn's disease. A Mediterranean pattern is reasonable and well tolerated; the Specific Carbohydrate Diet has some supportive data but was not superior to a Mediterranean diet when tested head to head in Crohn's. During a flare, lower residue food is easier to tolerate; during remission, variety and fiber are worth rebuilding. ↩
  12. On fish oil: a Cochrane review of three trials in 138 people with ulcerative colitis in remission found a similar relapse rate on omega-⁠3 and on control (risk ratio 1.02) and no evidence that it keeps ulcerative colitis in remission, PubMed 17636844. ↩
  13. On boswellia: in a 1997 trial in people with active ulcerative colitis, Boswellia serrata gum resin 350 mg three times daily for 6 weeks gave remission in 82%, against 75% on an aminosalicylate, PubMed 9049593. A review of herbal products tested in double-blind trials in IBD found that most of the evidence comes from single small trials with short follow-up, and that long-term effects and safety are not established, PubMed 31701598. ↩
  14. On conventional treatment: mesalamine and related 5-⁠aminosalicylates are first-line for mild to moderate disease, including topical formulations for distal disease which are often underused. Corticosteroids induce but do not maintain remission. Thiopurines, anti-TNF agents, vedolizumab, ustekinumab and JAK inhibitors are used for moderate to severe disease. Colectomy is curative for the colitis itself. ↩
  15. On advanced therapies: the American Gastroenterological Association's 2024 living guideline recommends infliximab, golimumab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ozanimod, etrasimod, risankizumab and guselkumab for adults with moderate to severe ulcerative colitis. It suggests early use of advanced therapies rather than gradual step-up after 5-⁠aminosalicylates fail, PubMed 39572132. ↩
  16. On dairy: a meta-analysis found lactose maldigestion more common in inflammatory bowel disease overall, but the raised risk held only for Crohn's disease affecting the small bowel; it concluded that maldigestion in IBD depends mainly on ethnic background rather than the disease, and that restricting dairy may harm bone health and the course of the disease, PubMed 27411934. ↩
  17. On curcumin and the liver: in seven Italian cases of acute hepatitis linked to turmeric supplements, every case involved a high-bioavailability, high-dose formulation; a systematic review found 23 further published cases, PubMed 32656820. ↩
  18. Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of long-term marine omega-⁠3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981-⁠1990. PubMed 34612056. Seven trials with 81,210 people followed for about 5 years: omega-⁠3 supplements were linked to a higher risk of atrial fibrillation (hazard ratio 1.25), more so in trials of more than 1 g a day (1.49), and the risk rose with each additional gram. ↩
  19. On iron in IBD: British Society of Gastroenterology guidelines note that a third of people with active IBD have iron-deficiency anemia, advise against iron tablets during active disease because inflammation blocks iron absorption, and advise intravenous iron first line for people with active IBD and moderate to severe anemia who cannot tolerate oral iron, PubMed 31562236. ↩
  20. On when a flare is severe: a review defines severe ulcerative colitis as more than six bloody stools a day with any one of a pulse over 90 beats a minute, a temperature over 100°F (37.8°C), anemia (hemoglobin under 10.5 g/dL) or a raised ESR, and calls it an indication for intensive intravenous treatment. Travis SP. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther. 2004, PubMed 15352901. ↩
  21. National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic. ↩
  22. On a blocked bowel: MedlinePlus lists the inability to pass gas, abdominal swelling and vomiting among the symptoms of intestinal obstruction; it names being unable to pass stool or gas as a warning sign, MedlinePlus (intestinal obstruction). ↩
  23. On age at diagnosis: the US National Institute of Diabetes and Digestive and Kidney Diseases states that ulcerative colitis is more likely to develop between the ages of 15 and 30, although it can develop at any age, NIDDK; a 2019 review describes a bimodal age distribution, with a first peak in the second or third decade of life and a second peak between 50 and 80 years of age. Gajendran M, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65(12):100851, PubMed 30837080. ↩